Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 19/20 | 0.42 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24350870 | 0.95 | MAP2K1 (0.44) | MAP2K1MAP2K2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL24906352 | 0.89 | MAP2K1 (0.39) | MAP2K1MAP2K2USP25 | |
| SCHEMBL24906170 | 0.86 | MAP2K1 (0.47) | MAP2K1MAP2K2 | |
| SCHEMBL24906315 | 0.86 | MAP2K1 (0.47) | MAP2K1MAP2K2 | |
| SCHEMBL26047253 | 0.86 | MAP2K1 (0.47) | MAP2K1MAP2K2 | |
| SCHEMBL24906181 | 0.86 | CSF1R (0.39) | MAP2K1MAP2K2USP25 | |
| SCHEMBL30034958 | 0.86 | MAP2K1 (0.55) | MAP2K1MAP2K2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL20565703 | 0.86 | MAP2K1 (0.55) | MAP2K1MAP2K2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL26047319 | 0.86 | MAP2K1 (0.43) | MAP2K1MAP2K2 | |
| SCHEMBL22045814 | 0.85 | MAP2K1 (0.43) | MAP2K1MAP2K2USP25 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4233834-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233865-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |